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ABSTRACT
The aim of this study was to evaluate the impact
of the meningococcal C conjugate vaccine on the
epidemiology of meningococcal C disease in
Greece. Data from the National Reference Labor-
atory for Meningococcal Disease and a question-
naire distributed to Greek paediatricians were
assessed. Since the introduction of the vaccine in
2001, 72% of Greek paediatricians have adminis-
tered it as one single dose to patients aged
‡12 months. This vaccination scheme has prob-
ably contributed to a dramatic decrease in the
number of meningococcal C infections, which
reached zero in 2004.
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International concern regarding meningococcal
disease has always been significant because of the
accompanying high mortality and possible long-
term sequelae. In Greece, sporadic use of the
polysaccharide vaccine against meningococci
belonging to groups A and C did not halt the
four-fold rise in cases of meningococcal disease,
caused predominantly by serogroup C meningo-
coccus (clone C:2a:P1.5), during 1996–1998 [1]
(National Reference Laboratory for Meningo-
coccal Disease, unpublished data). Although it is
not yet included in the official vaccination sched-
ule, Greek paediatricians have subsequently been
administering the meningococcal C (Men-C) con-
jugate vaccine since its introduction in January
2001. The present study concerned the entire
paediatric population aged £15 years in Greece
between January 1993 and June 2006. The 0.5-mL
Men-C vaccine contains 10 lg of Neisseria menin-
gitidis C (serotype C11) oligosaccharide, conju-
gated with either CRM197 Corynebacterium
diphtheriae protein (Wyeth, Madison, NJ, USA)
or with tetanus toxoid (Baxter Vaccines, Wein,
Austria). The study was approved by the ethics
committee of the P & A Kyriakou Children’s
Hospital, Athens, Greece.
A questionnaire focusing on Men-C vaccination
practice was distributed to 493 paediatricians. In
total, 348 responses were received; 65.1% of
responders answered the questionnaire during
three successive nationwide conferences, while
the remaining responders were distributed ran-
domly throughout the country. In total, 70.8% of
responders were practising in the two largest
cities (Athens and Thessalonica). Interpretation of
data was based on the following assumptions: (i)
that all children have visited a paediatrician at
least once; (ii) that the number of children each
paediatrician followed-up was the same; and (iii)
that all paediatricians completed the question-
naire accurately. However, although interpret-
ation of questionnaire data would be impossible
without the assumption that the number of
children each paediatrician followed-up was the
same, this may not be realistic.
The number of vaccine doses sold, which was
obtained from a national statistical surveillance
programme and the suppliers’ logistics depart-
ments, together with the number of live births,
were used to determine a rough estimate of
vaccination coverage. Problems concerning the
use of vaccine sales data as a surrogate marker
were taken into consideration, including a failure
to use the vaccine (which was the most frequent
reason), an ineffective vaccine, or an erroneous
route of administration.
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All statistical tests for normality were conducted
with the Shapiro–Wilk test, while median compar-
isons of independent samples were performed
with the Mann–Whitney test. All statistical values
were considered significant at p £0.05.
All paediatricians questioned confirmed
administration of the conjugate vaccine. There
was no statistically significant difference in vac-
cination practice among paediatricians in Athens
and the rest of the country. The preferred regimen
of 72.0% of paediatricians was to give a single
dose at an age of ‡12 months. The age at which the
vaccine was administered varied from 2 months
to a maximum of 24 months, and vaccination
coverage for this specific age group was almost
100%. Each year, vaccinated children were added
to the pool aged £15 years, while unvaccinated
children were excluded. Therefore, vaccination
coverage rose from an estimated 20.7% in 2001 to
51.4% of the total Greek paediatric population
(n = 1.5 million) in 2005 (Fig. 1).
In 1996–1998, i.e., before the introduction of the
conjugate vaccines, there was an increase in
meningococcal C cases [1]. Between 1999 and
2001, a decline in cases to pre-1996–1998 levels was
observed, with a further decrease being observed
in 2002 after the introduction of the Men-C vaccine.
No cases of meningococcal C infection were
reported during 2004, although there were three
cases in 2005, and four cases in the first 6 months of
2006. The proportion of meningitis cases caused by
serotypes B, A, W135 and Y changed, and while
serogroup B predominated, the A serotype became
the second most frequent [2] (National Reference
Laboratory for Meningococcal disease, unpub-
lished data) (Table 1). After 1998, serogroup C
disease decreased, probably as a result of herd
immunity that developed after the circulation of
the epidemic clone in the community in previous
years. The introduction of the conjugate vaccine
during 2001 was followed by almost complete
elimination of serogroup C disease from the
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Fig.1. Cases of meningococcal C
disease in Greece (squares) between
January 1993 and May 2006, and
vaccination coverage (circles) of
children aged 0–15 years since the
introduction of the Men-C vaccine in
2001.
Table 1. Distribution of meningococcal serogroups between 1993 and 2004 (data collected from the National Meningo-
coccal Reference Laboratory, Athens, Greece)
Year
No. of
specimens
Serogroup
B C A W-135 and Y NG
n % n % n % n % n %
1993 29 14 48.3 11 37.3 0 0 5 17.2
1994 30 16 53.3 13 43.4 0 0 1 3.4
1995 32 16 50.0 15 46.9 1 3.1 0 0
1996 88 25 28.4 48 54.5 0 6 6.8 7 7.9
1997 72 25 34.7 46 63.9 1 1.4 0 0
1998 109 49 44.9 46 42.2 5 4.6 3 2.8 6 5.5
1999 127 70 55.1 29 22.8 6 4.7 3 2.3 19 15.0
2000 161 80 49.6 20 12.4 9 5.6 15 9.3 37 23.0
2001 158 69 43.7 14 8.9 31 19.6 11 7.0 33 20.9
2002 174 75 43.1 11 6.3 19 10.9 20 11.5 49 28.1
2003 101 53 52.5 2 2.0 17 16.8 6 5.9 23 22.8
2004 63 43 68.2 0 3 4.8 0 17 27.0
NG, not grouped.
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population studied. Although this reduction may
be the result of a natural variation in meningococ-
cal disease epidemiology, it is likely that the
introduction of vaccine contributed considerably
to the reduction.
In France, a vaccination campaign triggered by
a rapid increase in cases of serogroup C disease
resulted in no new cases [3], while surveillance
following the introduction of the vaccine in Spain
revealed a reduction in the incidence of serogroup
C disease [4]. In locations where recent outbreaks
have been reported, e.g., Quebec, Canada, an
expanded vaccination strategy might be needed
[5]. In the UK, although there has been a reduc-
tion of up to 86.7% in the number of cases of
meningococcal C disease, a decline in the number
of related deaths (67 in 1999; five in 2001) and a
66.0% reduction in the carriage of serogroup C
meningococci in the 1-year period following the
introduction of the Men-C vaccine [6,7], predic-
tive models suggested the need for catch-up
campaigns to induce herd immunity [8].
Although the long-term effectiveness of the vac-
cine is being studied, accumulated data suggest
that a booster dose may be needed [9,10]. The UK
Department of Health will change the timing of
the three doses of the Men-C vaccine from ages 2,
3 and 4 months to ages 3 and 4 months, with a
booster at 12 months, as the protection offered by
the original dosage scheme wanes 1 year after the
last dose (http://www.dh.gov.uk/Publications
AndStatistics/PressReleases/PressReleasesNotices/
fs/en?CONTENT_ID = 4128036&chk = PI8e57).
Immunisation of infants aged ‡1 year is less
costly than administration of two or three doses
during the first year of life, and was shown in
the present study to contribute effectively to
disease control. Further enhanced surveillance of
meningococcal disease is required to evaluate the
effectiveness of the vaccine when administered at
this age.
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